Lupin informs about inspection updates
Lupin has informed that the US FDA has concluded an inspection at manufacturing facility located in Somerset, New Jersey, USA. The inspection was conducted from April 13, 2026 to April 17, 2026 and closed with the issuance of a Form-483 with three observations. They will address the observations and respond to the US FDA within the stipulated timeframe. They are committed to be compliant with CGMP standards across all its facilities. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations.
The above information is a part of company’s filings submitted to BSE.
